Biogen Stock News

The Centers for Medicare and Medicaid may ensure the commercial death of Biogen's controversial Alzheimer's drug. And that leads at least one analyst to wonder if more radical steps need to be taken.

Groups supporting Alzheimer patients are putting pressure on the Centers for Medicare and Medicaid Services to reverse a preliminary decision that severely limits coverage

Los Angeles, USA, Jan. 17, 2022 (GLOBE NEWSWIRE) -- Parkinson''s Disease Pipeline Offers Promising New Options for Treatment | DelveInsight DelveInsight''s "Parkinson''s Disease Pipeline Insight" report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Parkinson''s Disease pipeline landscapes. The report comprises Parkinson''s Disease pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Parkinson''s Disease therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Parkinson''s Disease pipeline products. Some of the key takeaways from the Parkinson''s Disease Pipeline Report Major Parkinson''s Disease companies such as Cerevel Therapeutics, Abbvie, Pharma Two B, Roche, Kissei Pharmaceutical, Peptron, Inc., Lundbeck A/S, AstraZeneca, Nobilis Therapeutics, Treefrog Therapeutics, Cantabio Pharmaceuticals, Anavex Life Sciences, Ipsen, Prevail Therapeutics, AFFiRiS, Sio Gene Therapies, UCB Pharma, Brain Neurotherapy Bio, Inc., Neuraly, Inc., NeuroDerm, BlueRock Therapeutics, Sun Pharma Advanced Research Company, Xoc Pharmaceuticals, Hong Kong WD Pharmaceutical, 1ST Biotherapeutics, Inc., Biogen, Denali Therapeutics, Inhibikase Therapeutics,Cerevance, Aspen Neuroscience,Prilenia Therapeutics,Cortexyme Inc.,Gain Therapeutics, Clexio Biosciences, Orpheris, Inc., Alkahest, Inc., and others are developing potential drug candidates to improve the Parkinson''s Disease treatment scenario.

Only if you're (really) brave.

The latest snub for Aduhelm does not bode well for this company's future.

As the prospects for its once-promising Alzheimer's drug continue to dim, Biogen Inc. ( BIIB , Financial) is reportedly exploring strategic options, including selling itself or acquiring a smaller bio

Aurinia Pharmaceuticals (AUPH) reversed an earlier decline and is now up 3.4% after a report indicated Biogen (BIIB) could potentially look to target the company.Aurinia (AUPH) was

After a sharp selloff on Wednesday in reaction to an unfavorable Medicare decision on its new Alzheimer’s therapy, Aduhelm, Biogen <> have recovered as analysts weighed in on…

The Food and Drug Administration placed Denali''s Alzheimer''s test on hold Thursday, sending DNLI stock into a dive.

Biogen Inc is working with investment bank Goldman Sachs to find potential targets for acquisitions, Stat News reported on Thursday, citing an unnamed source.

The biotech sector is prone to surprise headlines. But these biotech stocks to buy today have had fallen so much that they hit bottom.

Shares of Biogen Inc. BIIB, -6.70% were down 0.9% in premarket trading on Thursday after Guggenheim analysts downgraded the stock to neutral, from buy. Analysts there cite the need to wait and see how

Stocks that traded heavily or had substantial price changes Wednesday: Dish Network, Ally Financial rise; Biogen, Carvana fall

Wednesday afternoon''s top analyst upgrades and downgrades included AbbVie, Biogen, DoorDash, Kratos Defense, PayPal and more.

The head of the body charged with administering Medicare said a proposed rule limiting access to Biogen''s (BIIB) controversial Alzheimer''s drug followed an evidence-based process.